|
Active substance |
atezolizumab |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
in combination with bevacizumab, paclitaxel and carboplatin, first-line treatment of adult patients with stage IV or recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) and whith liver metastases and/or who have an EGFR mutation or ALK translocation. |
|
Public documents |
|
|
Last update |
30/03/2020 |
Atezolizumab
Last updated on 03/04/2024